Latest filings (excl ownership)
8-K
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
4 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Departure of Directors or Certain Officers
21 Dec 23
ARS
2022 FY
Annual report to shareholders
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
DEF 14A
Definitive proxy
13 Nov 23
8-K
Entry into a Material Definitive Agreement
6 Nov 23
PRE 14A
Preliminary proxy
3 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Study will evaluate drug’s potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients
19 Jul 23
8-K
Departure of Directors or Certain Officers
22 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Apr 23
8-K
Submission of Matters to a Vote of Security Holders
14 Apr 23
DEF 14A
Definitive proxy
27 Mar 23
10-K
2022 FY
Annual report
21 Mar 23
PRE 14A
Preliminary proxy
20 Mar 23
8-K
Results of Operations and Financial Condition
7 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
17 Feb 23
DEF 14A
Definitive proxy
9 Jan 23
PRE 14A
Preliminary proxy
28 Dec 22
8-K
Amendments to Articles of Incorporation or Bylaws
28 Dec 22
424B3
Prospectus supplement
28 Dec 22
EFFECT
Notice of effectiveness
28 Dec 22
CORRESP
Correspondence with SEC
22 Dec 22
UPLOAD
Letter from SEC
22 Dec 22
S-3
Shelf registration
16 Dec 22
8-K
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2
16 Dec 22
S-8
Registration of securities for employees
22 Nov 22
8-K
Amendments to Articles of Incorporation or Bylaws
22 Nov 22
8-K
Synaptogenix Announces $15 Million Private Placement with Existing Investors
18 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Departure of Directors or Certain Officers
12 Oct 22
DEFA14A
Additional proxy soliciting materials
25 Aug 22
DEF 14A
Definitive proxy
25 Aug 22
8-K
Changes in Registrant's Certifying Accountant
16 Aug 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
EFFECT
Notice of effectiveness
28 Apr 22
Latest ownership filings
4
William S. Singer
10 Apr 24
4
Joshua Silverman
10 Apr 24
4
JONATHAN SCHECHTER
10 Apr 24
4
Bruce Bernstein
10 Apr 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
JONATHAN SCHECHTER
31 Mar 23
4
William S. Singer
31 Mar 23
4
Bruce Bernstein
31 Mar 23
4
Joshua Silverman
31 Mar 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
SC 13G/A
HAYWOOD GEORGE WEAVER
18 Jan 23
4
William S. Singer
20 Dec 22
4
ROBERT WEINSTEIN
20 Dec 22
4
Joshua Silverman
20 Dec 22
4
JONATHAN SCHECHTER
20 Dec 22
4
Daniel L. Alkon
20 Dec 22
4
Bruce Bernstein
20 Dec 22
4
ALAN J TUCHMAN
20 Dec 22
4/A
ROBERT WEINSTEIN
1 Dec 22
4/A
Daniel L. Alkon
1 Dec 22
4/A
Joshua Silverman
1 Dec 22
4/A
William S. Singer
1 Dec 22
4/A
Joshua Silverman
1 Dec 22
4/A
Daniel L. Alkon
1 Dec 22
4/A
Bruce Bernstein
1 Dec 22
4/A
ALAN J TUCHMAN
1 Dec 22
4
Bruce Bernstein
17 Nov 22
4
Joshua Silverman
17 Nov 22
4
ROBERT WEINSTEIN
17 Nov 22
4
Daniel L. Alkon
17 Nov 22
4
William S. Singer
17 Nov 22
4
ALAN J TUCHMAN
17 Nov 22
4
JONATHAN SCHECHTER
17 Nov 22
4/A
William S. Singer
23 Jun 22
4/A
Joshua Silverman
23 Jun 22
4/A
JONATHAN SCHECHTER
23 Jun 22
4/A
Bruce Bernstein
23 Jun 22
4
William S. Singer
6 Apr 22
4
Joshua Silverman
6 Apr 22
4
JONATHAN SCHECHTER
6 Apr 22